




OPEN

Randomized clinical trial shows no substantial modulation of empathy-related neural activation by intranasal oxytocin in autism

Annalina V. Mayer^{1,5}, Anne-Kathrin Wermter^{2,5}, Sanna Stroth², Peter Alter⁴, Michael Haberhausen², Thomas Stehr², Frieder M. Paulus¹, Sören Krach¹ & Inge Kamp-Becker^{2,3}

Evidence suggests that intranasal application of oxytocin facilitates empathy and modulates its underlying neural processes, which are often impaired in individuals with autism spectrum disorders (ASD). Oxytocin has therefore been considered a promising candidate for the treatment of social difficulties in ASD. However, evidence linking oxytocin treatment to social behavior and brain function in ASD is limited and heterogeneous effects might depend on variations in the oxytocin-receptor gene (*OXTR*). We examined 25 male ASD patients without intellectual disability in a double-blind, cross-over, placebo-controlled fMRI-protocol, in which a single dose of oxytocin or placebo was applied intranasally. Patients performed three experiments in the MRI examining empathy for other's physical pain, basic emotions, and social pain. All participants were genotyped for the rs53576 single-nucleotide polymorphism of the *OXTR*. Oxytocin increased bilateral amygdala responsiveness during the physical pain task for both painful and neutral stimuli. Other than that, there were no effects of oxytocin treatment. *OXTR* genotype did not significantly interact with oxytocin treatment. Our results contribute to the growing body of empirical literature suggesting heterogeneous effects of oxytocin administration in ASD. To draw clinically relevant conclusions regarding the usefulness of oxytocin treatment, however, empirical studies need to consider methods of delivery, dose, and moderating individual factors more carefully in larger samples.

Abbreviations

AAL	Automated anatomic labeling
ACC	Anterior cingulate cortex
ADI-R	Autism diagnostic interview-revised
ADOS	Autism diagnostic observation schedule
ASD	Autism spectrum disorders
EN	Emotional neutral faces (task condition)
EPI	Echo planar imaging
fMRI	Functional magnetic resonance imaging
FWE	Family-wise error (correction)
HAP	Happy faces (task condition)
<i>OXTR</i>	Oxytocin receptor gene
PN	Physical neutral (task condition)

¹Department of Psychiatry and Psychotherapy, Social Neuroscience Lab, University of Lübeck, Lübeck, Germany. ²Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Philipps University of Marburg, Marburg, Germany. ³Marburg Center for Mind, Brain and Behavior (CMBB), Philipps University of Marburg, Marburg, Germany. ⁴Department of Medicine, Pulmonary and Critical Care Medicine, and Member of the German Center for Lung Research (DZL), Philipps University of Marburg, Marburg, Germany. ⁵These authors contributed equally: Annalina V. Mayer and Anne-Kathrin Wermter. ✉email: ann.mayer@uni-luebeck.de

PP	Physical pain (task condition)
ROI	Regions of interest
SAD	Sad faces (task condition)
SN	Social neutral (task condition)
SNP	Single nucleotide polymorphism
SP	Social pain (task condition)

Autism spectrum disorders (ASD) are a group of neuro-developmental disorders characterized by impairments in social communication, social interaction and restrictive, repetitive patterns of behavior¹. ASD are predominantly genetic in origin, with heritability estimates of around 80%². One symptom reported by individuals with ASD are difficulties in intuitively empathizing with others' emotional states, especially in situations that require an integration of complex social information^{3,4}. These difficulties have been associated with anatomical and functional differences in the empathy network^{5–10}. This network, including the anterior cingulate cortex (ACC) and the anterior insula, encodes for both one's own, as well as others' bodily, mental, and emotional states¹¹. This has led to the idea that humans are able to understand others through an embodied simulation of their own internal states¹².

Long known for its role in childbirth and lactation¹³, the hormone and neuropeptide oxytocin has also gained attention in the field of psychology and neuroscience as a modulator of various social behaviors¹⁴. Importantly, intranasal administration of oxytocin has also been found to enhance the ability to share others' affective and mental states in healthy individuals^{15,16}. In this context, the insula¹⁷ as well as the amygdala seem to be key target regions in the brain, with oxytocin modulating amygdala responsiveness to emotional faces^{18–22} or social stimuli in general²³. This fits well with findings showing prominent expressions of oxytocin receptors in striatal and limbic regions, such as the amygdala, as well as the ACC²⁴, which have strong connections with the frontal cortex and the anterior insula. Further, variations of the oxytocin receptor gene (*OXTR*) have been associated with individual differences in the capacity and tendency to empathize with others' emotional states in healthy individuals^{25–30} and related brain function in individuals with ASD³¹.

With oxytocin pathways being involved in processes related to sharing others' emotions, it has been suggested that alterations in the oxytocin system may also be linked to social impairments in ASD. For example, some studies have found lower levels of plasma oxytocin in ASD patients compared to typically developing individuals^{32–34}, but results are overall inconsistent^{35,36}. Other studies suggest that lower plasma oxytocin levels relate to general social functioning rather than the diagnosis of ASD³⁵. Genetic association studies have further linked variation in the *OXTR* with ASD and symptoms in the social domain³⁷. Meta-analyses indicated several candidate single nucleotide polymorphisms (SNPs) in the *OXTR* to have significant association both with ASD³⁸ and symptom severity³⁹. Especially the rs53576 SNP (G > A) has been shown to modulate social cognition both within ASD and the general population⁴⁰. Initial findings suggest that the rs53576 A allele may be a central part of haplotypes associated with ASD⁴¹, which is in line with studies linking this allele to lower levels of empathy²⁵, as well as structural and functional changes in hypothalamus and amygdala in healthy samples⁴². Specifically, it has been shown that A allele carriers have reduced amygdala activation during the processing of faces compared to non-carriers⁴².

Several clinical studies have also investigated the potential of intranasal oxytocin as a treatment for socio-cognitive, behavioral, and socio-affective symptoms of ASD. So far, these studies cannot provide a certain conclusion about oxytocin's therapeutic potential^{43–47}. Results from early studies however suggest that oxytocin increases the attention to social signals and thus may enhance empathy and emotion recognition in individuals with ASD. For example, oxytocin has been shown to increase gazing time on the eye region³³, and to improve performance on the Reading the Mind in the Eyes Task in adults and adolescents with ASD^{48,49}. Imaging studies have provided preliminary evidence that oxytocin influences the ability to understand others' mental and emotional states by enhancing activation of brain regions within the empathy network, such as the anterior insula⁵⁰. Similarly, oxytocin administration has been shown to increase amygdala activation during face processing specifically in adults with ASD, accompanied by improvements in emotion recognition^{51,52}.

However, it has been discussed that the effects of intranasal oxytocin may not be the same for all individuals, but instead depend on stable individual differences, which might reflect variation in the endogenous oxytocin system, including genetic factors⁵³. The *OXTR* might be specifically relevant because of its associations with trait empathy and autistic symptoms. Several studies indeed suggest that oxytocin effects on behavior^{54–56} and brain function^{57–59} are modulated by *OXTR* genotype. Considering relevant *OXTR* SNPs could thus be a means of identifying those individuals with ASD that are most responsive to intranasal oxytocin treatment^{44,60}, and examining moderating effects of genotype on neural activation as an intermediate phenotype could help to achieve a deeper understanding of how *OXTR* genotypes influence social behavior¹⁴.

To date, it is still unclear whether *OXTR* genotype moderates the effects of intranasal oxytocin on neural activity when empathizing with others. In the present clinical trial, we used functional magnetic resonance imaging (fMRI) to investigate effects of a single dose of oxytocin on neural correlates of sharing others' inner states in a sample of young males with ASD without intellectual disability. We focused our analyses on the ACC and anterior insula as parts of the empathy network, as well as the amygdala. Furthermore, to account for individual factors possibly modulating oxytocin effects, we specifically tested the effect of genetic variation on the rs53576 SNP of the *OXTR*. Based on previous findings, we expected increased activation of regions within the empathy network after oxytocin compared to placebo. Further, it was hypothesized that carriers of the risk allele (AA and GA) would show altered activation in empathy-associated networks compared to non-carriers after oxytocin administration.

	Total sample	Risk allele (AA, GA)	No risk allele (GG)	<i>p</i>
	(<i>N</i> = 25)	(<i>n</i> = 15)	(<i>n</i> = 10)	
At time of study participation				
Age	22.9 (4.7)	23.1 (3.5)	22.6 (6.3)	0.06
IQ	107.3 (18.1)	111.4 (16.5)	103.4 (20.2)	0.32
AQ	28.6 (9.9)	29.9 (9.5)	26.7 (10.6)	0.44
EQ	25.8 (14.4)	23.6 (12.6)	29.2 (16.8)	0.35
ADOS SA	9.1 (4.4)	9.5 (4.8)	8.6 (4.0)	0.64
ADOS RRB	0.9 (1.0)	0.8 (1.0)	1.1 (1.1)	0.49
ADOS SA + RRB	10.1 (4.6)	10.3 (5.0)	9.7 (4.1)	0.77
ADOS Comparison Score	5.5 (2.6)	5.6 (2.7)	5.3 (2.4)	0.78
Comorbidities (ICD-10 Code)		3 × F3 1 × F42	3 × F3 1 × F42 1 × F40 1 × F90	
At time of diagnosis				
Age at time of diagnosis	13.1 (4.7)	13.4 (4.0)	13.1 (5.3)	0.88
ADOS SA	11.5 (3.9)	12.9 (3.7)	9.5 (3.3)	0.03
ADOS RRB	1.9 (1.5)	2.1 (1.6)	1.7 (1.5)	0.50
ADOS SA + RRB	13.5 (4.9)	15.1 (5.1)	11.2 (3.7)	0.06
ADOS Comparison Score	7.3 (2.1)	8.1 (1.9)	6.3 (2.0)	0.03
ADI-R social interaction	17.8 (5.2)	17.6 (5.2)	18.3 (5.5)	0.74
ADI-R communication	13.7 (4.6)	13.4 (3.7)	14.3 (5.6)	0.62
ADI-R stereotyped behavior	5.7 (2.7)	5.6 (3.0)	5.8 (2.1)	0.91

Table 1. Sample characteristics. Means, standard deviations (in parentheses) and between-group comparisons on clinical measures in risk allele carriers and non-carriers. AQ Autism Spectrum Quotient⁶⁵, EQ Empathy Quotient⁶⁶, ADOS Autism Diagnostic Observational Schedule^{61,67}, ADOS SA ADOS Social Affect Score, ADOS RRB ADOS Repetitive and Restricted Behavior Score, ADI-R Autism Diagnostic Interview-Revised⁶². *p*-values derive from two-sample *t*-tests comparing carriers of the risk allele A (AA, GA) to non-carriers (GG).

Methods

Patients. Twenty-seven male patients with ASD, aged between 15 and 33 years ($M = 22.91$, $SD = 4.72$ years), were recruited from the Outpatient Clinic for autism spectrum disorders at Marburg University Hospital in Marburg, Germany. All matched the DSM 5 criteria of ASD, had a confirmed ICD-10 diagnosis of autism ($n = 4$) or Asperger's syndrome ($n = 23$) and had undergone standardized diagnostic procedure at a mean age of 13.1 years ($SD = 4.73$ years) including the Autism Diagnostic Observation Schedule (ADOS⁶¹), the Autism Diagnostic Interview-Revised (ADI-R⁶²) and IQ testing with the Wechsler Intelligence Scale for Children⁶³. Current symptom level was assessed with Module 4 of the ADOS at the time of participation (Table 1). Comorbid psychiatric symptoms were assessed using the Diagnostic Interview for Mental Disorders⁶⁴. Patients were not included if they had a verbal IQ below 70, were left-handed or suffered from severe comorbid neurological (e.g. epilepsy), metabolic, endocrinological or cardiovascular conditions. The study was approved by the local ethics committee of the medical faculty of the Philipps-University in Marburg, Germany (214/12 A-ff) and carried out in compliance with the Declaration of Helsinki of 1975, as revised in 2008. All patients received detailed medical information about the study and gave their full informed consent in writing. For patients under the age of 18 years, informed consent was also obtained from their parents or legal guardians. Two patients were excluded after the first study visit because of unexpected clinical findings in one case and subjective negative experiences (nightmares) in another case, leaving data from $n = 25$ patients to be analyzed. Due to technical difficulties during the MRI scan, two patients were excluded from the analyses of the basic emotions experiment, and four were excluded from the analyses of the social pain experiment (see Supplementary Fig. S1 for CONSORT diagram of patient recruitment and study flow).

Genotyping for OXTR rs53576. The participants included in this study were drawn from a larger sample of 100 patients with ASD that was analyzed for 22 SNPs in the OXTR and its 5' region including rs53576⁶⁸.

Clinical trial design. This randomized controlled trial was preregistered at the European Union Clinical Trials Register (EudraCT 2012-003750-89; <https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003750-89/DE>; registered 21/11/2012). The trial was stopped prematurely because of poor recruitment (see Supplementary Methods).

This was a monocentric, randomized, double-blind, placebo-controlled, cross-over study. Patients were invited to three visits: an initial visit, including study information, a physical examination, and confirmatory diagnostic procedures regarding the ASD diagnosis, and two MRI sessions that were between 7 and 21 days apart ($Mdn = 7$). Following a medical examination at the beginning of each MRI session, patients received a single dose (24 IU







	Stimuli		Rating
PP	Pain	Neutral	How painful is this situation? 1–2–3–4–5 not at all -----very much
			
EMO	Happy	Neutral	How does this person feel? 1–2–3–4–5 very sad ----- very happy
			
SP	Pain	Neutral	How embarrassed is this person? 1–2–3–4–5 not at all -----very much
			

Figure 1. Stimuli and rating questions of the three experiments. In all three experiments, patients were required to view stimulus pictures and respond to a subsequent rating question. The upper row shows two example stimuli of the physical pain (PP) experiment, reflecting the two stimulus categories used in the experiment, and the respective rating question. Example stimuli and rating questions for the basic emotions (EMO) and social pain (SP) experiments are displayed in the middle and lower row. Stimuli for the basic emotions experiment were taken from the Karolinska Directed Emotional Faces database⁶⁹, which is publicly available and may be used for non-commercial scientific research purposes (<https://www.kdef.se/>; stimuli shown here: BF02HAS, BF02NES, BF02SAS). In the physical pain and basic emotions experiment, patients were instructed to look at the photograph for 4.5 s and to rate the intensity of pain or the quality of emotion that the depicted person would experience. In the social pain experiment, sketches showed a protagonist, indicated by a red arrow above their head, in potentially embarrassing (socially painful) or neutral situations. Each sketch was accompanied by a sentence introducing the current scenario [for these specific situations: “You are on the pavement: a car driver knocks over a trash can while backing into a parking space” (Pain); “You are in the city: a cyclist turns right” (Neutral)]. Patients were instructed to look at each sketch for 12 s and to subsequently rate the intensity of the embarrassment the protagonist would feel in the respective scenario. The length of the rating phase was 3 s in all experiments.

for patients aged ≥ 18 years, $n = 20$; 18 IU for patients between 15 and 17 years, $n = 5$) of oxytocin or placebo intranasally. Patients were randomly assigned to receive oxytocin ($n = 14$) or placebo ($n = 11$) first. 45 min after substance administration they entered the MRI and performed three consecutive experiments. No adverse side-effects of the nasal spray were observed. For details on the assessment of side effects see Supplementary Methods and Supplementary Tables S7 and S8.

Stimuli and paradigms. The fMRI experiments examined participants' evaluations of and neural responses to others' social pain, expression of basic emotions and physical pain (see Fig. 1 for stimulus examples, rating questions and timings). The experiments were conducted in exactly this order, using parallel versions during the first and second MRI session. In all experiments, participants viewed pictures that were presented to them on a screen. In the social pain task, pictures were hand-drawn sketches showing a person in an embarrassing (social pain, SP) or neutral (social neutral, SN) social situation. In the basic emotions task, patients viewed photographs of faces displaying a happy (HAP), sad (SAD) or neutral (EN) expression. In the physical pain task, pictures showed a person's hand or foot in a painful (physical pain, PP) or non-painful (physical neutral, PN) situation. After each picture, participants were required to rate the intensity of pain or quality of emotion the depicted person would experience in the scenario (1 = no pain/very sad, 5 = very strong pain/very happy) within a 3-s time window using a button press of the right hand (see Supplementary Methods for task details). In total, the social pain task lasted 16 min, the basic emotions task lasted 8 min and the physical pain task lasted 8 min.

Functional MRI data acquisition. Participants were scanned at 3 Tesla (Siemens Magnetom Trio, Erlangen, Germany) with 36 near-axial slices and a distance factor of 10% providing whole brain coverage. For the acquisition of functional images, an echo planar imaging (EPI) sequence was used (TR = 2.2 s, TE = 30 ms, flip angle = 90, slice thickness = 3 mm, FoV = 190 × 190 mm). In total, 402 functional images were obtained for the social pain experiment, 218 images were obtained for the basic emotions experiment, and 210 images were obtained for the physical pain experiment. To rule out potential anatomical abnormalities, high resolution images with a T1-weighted 3D MP-RAGE sequence were acquired (TR = 1900 ms, TE = 2.52 ms, number of slices = 176 (sagittal), slice thickness = 1 mm, FoV = 256 × 256 mm, voxel size = 1 × 1 × 1 mm).

Data analysis. Behavioral data. Behavioral data analysis was conducted using IBM SPSS Statistics 22 (Armonk, NY: IBM Corp. Released 2013). To examine the effects of treatment on stimulus ratings, we calculated two-way repeated-measures ANOVAs for each experiment, including treatment (oxytocin, placebo) and stimulus category as within-subject factors. Further, genotype was added as a covariate. We applied an allele-load model and coded genotype in a linear fashion (AA < GA < GG), since trait empathy has been found to vary as a function of the number of risk alleles on the rs53576 SNP²⁹. For additional analyses examining genotype-treatment interactions on differential behavioral responses during the three experiments, see Supplementary Information. Paired t-tests were calculated to assess mean rating differences of oxytocin and placebo within each stimulus category. P-values were corrected for multiple comparisons using the Holm–Bonferroni method⁷⁰.

To explore possible interactions of treatment with participant age, received dose (18 vs. 24 IU, depending on age), and order of treatment (oxytocin first, placebo first), we calculated three additional repeated-measures ANOVAs per experiment, each with stimulus category and treatment as within-subject factors, genotype as covariate, and age, dose or order as additional covariate or between-subjects variable.

Functional MRI data. Functional MRI data were preprocessed and analyzed using the statistical parametric mapping software package (SPM12, retrieved from www.fil.ion.ucl.ac.uk/spm). For each session, the volumes were corrected for slice timing, head motion, and spatially normalized to the Montreal Neurological Institute standard space by applying non-linear transformations obtained from a segmentation of the mean EPI image. The normalized volumes were resliced with a voxel size of 2 × 2 × 2 mm, smoothed with an 8 mm full-width half-maximum isotropic Gaussian kernel and high-pass filtered with a cutoff period of 128 s. Statistical analyses were then performed using a mixed-effects, two-level procedure for each experiment.

For every fMRI experiment, we used analog procedures in the first- and second-level analyses. In the first-level analysis conducted for each subject and session, we included regressors modeling the hemodynamic responses to each stimulus category (i.e., SP and SN for social pain, HAP, SAD and EN for basic emotions and PP and PN for physical pain), as well as the rating period. Six parameters modeling head motion on a scan-to-scan basis were added as regressors to account for noise. The resulting β -maps of activation during each stimulus category were used in the analysis on the second level. Here, we defined random-effects general linear models with the two within-subject factors treatment (oxytocin, placebo) and stimulus category. Genotype was included as a covariate interacting with treatment. For additional analyses examining genotype-treatment interactions on responses within the regions of interest, see Supplementary Information. To explore potential moderating effects of age, dose, and order, we defined three additional general linear models per experiment including the covariate of interest in interaction with treatment. All fMRI results were family-wise error (FWE)-corrected for multiple comparisons on the voxel-level in both whole-brain and regions of interest (ROI) analyses.

Regions of interest analyses. Because of the pivotal role of the ACC and anterior insula in the experience of physical and social pain^{71–73} and the amygdala being a target region for oxytocin effects^{16,18,52}, we used anatomically defined ROIs in all three experiments to constrain the search space to these key areas. Masks of the ACC and amygdala were created using the automated anatomic labeling atlas (AAL)⁷⁴ integrated in the WFU PickAtlas⁷⁵. Since the AAL does not differentiate anterior and posterior sections of the insula, we used a validated three-cluster parcellation scheme to obtain a valid anterior insula mask⁷⁶. We chose two clusters specified as dorsal and ventral anterior insula and merged them to a single mask for left and right anterior insula, respectively. All ROI analyses were conducted using the small-volume correction as implemented in SPM12. Location and shape of all ROIs are displayed in Fig. 2A.

Results

Physical pain. Behavioral data. Mean stimulus ratings after oxytocin and placebo are shown in Table 2. Participants with ASD clearly distinguished between PP and PN, as indicated by a significant main effect of category on stimulus ratings ($F(1,23) = 901.89, p < 0.001$, partial $\eta^2 = 0.975$). There were no significant main effects of treatment or *OXTR* genotype, and no significant interaction effects.

Controlling for age, dose, and order of treatment did not change the magnitude of these effects (Supplementary Table S10). However, age was positively associated with mean stimulus ratings ($F(1,22) = 6.49, p = 0.018$, partial $\eta^2 = 0.228$). A post-hoc correlation analysis indicated that older participants gave higher mean ratings of physical pain regardless of stimulus category ($r(23) = 0.49, p = 0.012$). Further, there was a significant treatment × order interaction ($F(1,22) = 10.95, p = 0.003$, partial $\eta^2 = 0.332$). Post-hoc t-tests suggested that this interaction was driven by the group that received oxytocin first, where average ratings were lower after oxytocin compared to placebo (mean difference = 0.17, $t(22) = 3.26, p(\text{corrected}) = 0.021, d = 0.83$).




Figure 2. Regions of Interest and task-related mean activations during all experiments. **A.** Size and location of predefined Regions of Interest (ROIs). ACC = Anterior cingulate cortex. Images created with MRIcroGL (<https://www.nitrc.org/projects/mricrogl/>). **B.** Mean contrast estimates for all ROIs, displayed separately for each examined contrast. AI anterior insula, AMY amygdala, a.u. arbitrary units. Data derived from $N = 25$ patients for the physical pain experiment, $N = 23$ for the basic emotions experiment, and $N = 21$ for the social pain experiment. Plots were created using the package ggplot2 in R^{77,78}.

Functional MRI data. Whole brain analyses indicated that PP, compared to PN, induced strong and consistent activations of brain regions that have been previously implicated in empathy for or others' physical pain⁷⁹, including ACC, anterior insula and supramarginal gyrus (Supplementary Table S5, Fig. 2B). Treatment effects were examined using the contrasts oxytocin > placebo, placebo > oxytocin and in interactions with stimulus category. On the whole-brain level, oxytocin was found to enhance average activation within the right amygdala and inferior temporal gyrus ($k = 11$, MNI coordinates: $34/0/-26$, $t(94) = 5.12$, $p_{FWE} = 0.017$), and left hippocampus ($k = 10$, $-34/-8/-22$, $t(94) = 5.10$, $p_{FWE} = 0.019$) compared to placebo. ROI analyses revealed that oxytocin also increased average left amygdala activation ($k = 29$, $-22/-2/-12$, $t(94) = 3.95$, $p_{FWE} = 0.007$), although this effect was more pronounced in the right amygdala ($k = 131$, $p_{FWE} < 0.001$). There were no significant interactions of stimulus category and treatment, and no main effects of *OXTR* genotype, both in whole-brain and ROI analyses. Whole-brain analyses however showed significant genotype-treatment interactions in the left precuneus ($k = 50$, $-2/-46/10$, $t(94) = 5.68$, $p_{FWE} = 0.002$) and white matter within the left frontal inferior orbital region ($k = 10$, $-24/30/-6$, $t(94) = 5.42$, $p_{FWE} = 0.006$). Here, genotype was more strongly associated with activation under placebo conditions than after oxytocin.

Controlling for age, dose, and order of treatment did not change the magnitude of these effects (Supplementary Fig. S2). Regardless of stimulus category or treatment, age was significantly correlated with activation of a

			Oxytocin		Placebo		p'	d
			M	SD	M	SD		
Ratings	Physical pain	PP	3.91	0.47	3.94	0.45	1.000	0.07
		PN	1.25	0.33	1.11	0.16	0.406	-0.54
	Basic emotions	SAD	1.62	0.25	1.49	0.31	0.429	-0.46
		HAP	4.44	0.40	4.54	0.40	1.000	0.25
		EN	2.77	0.21	2.82	0.22	1.000	0.23
	Social pain	SP	4.04	0.42	3.99	0.34	1.000	-0.13
SN		1.22	0.37	1.12	0.21	1.000	-0.33	
RTs (ms)	Physical pain	PP	765	254	737	267	1.000	-0.11
		PN	698	248	694	239	1.000	-0.02
	Basic emotions	SAD	873	305	774	264	0.492	-0.35
		HAP	737	244	697	272	1.000	-0.16
		EN	706	269	709	253	1.000	0.01
	Social pain	SP	974	328	972	410	1.000	-0.01
SN		892	280	774	305	0.726	-0.40	

Table 2. Summary of behavioral data. p -values derive from paired t -tests comparing mean ratings after oxytocin and placebo administration. Values in the p' -column represent p -values adjusted for multiple comparisons using the Holm-Bonferroni correction while keeping the significance level of $p < 0.05$ constant. p' -values of 1.000 denote upper bound estimates. Data derived from $n = 25$ patients for the physical pain experiment, $n = 23$ for the basic emotions experiment, and $n = 21$ for the social pain experiment. RT Reaction time, PP physical pain, PN physical neutral, SAD Sad, HAP Happy, EN emotional neutral, SP social pain, SN social neutral, M mean, SD standard deviation.

small cluster within the left superior parietal lobe ($k = 5$, $-30/-54/58$, $F(1,92) = 30.04$, $p_{FWE} = 0.009$). Age, dose, and order did not significantly interact with treatment.

Basic emotions. *Behavioral data.* A main effect of category was observed, indicating that patients clearly distinguished the emotional expressions of the shown faces ($F(2,42) = 486.8$, $p < 0.001$, partial $\eta^2 = 0.959$). Further, the interaction of category and treatment was significant ($F(2,42) = 8.10$, $p = 0.001$, partial $\eta^2 = 0.278$). However, post-hoc comparisons could not detect significant mean differences between ratings after oxytocin and placebo when correcting for multiple comparisons (Table 2). There were no significant main effects of treatment or $OXTR$ genotype, and no significant interaction effects.

When controlling for age, the treatment \times category effect was no longer significant, and there was a significant main effect of genotype on mean ratings when controlling for dose ($F(1,20) = 4.75$; $p = 0.041$, partial $\eta^2 = 0.192$). Otherwise, controlling for age, dose and order did not influence treatment effects on ratings (Supplementary Table S11). There was a main effect of dose on mean stimulus ratings ($F(1,20) = 7.65$, $p = 0.012$, partial $\eta^2 = 0.277$; 18 IU: $M = 3.03$, $SD = 0.094$, $N = 5$; 24 IU: $M = 2.93$, $SD = 0.110$, $N = 18$). Age, dose, and order did not significantly interact with treatment.

Functional MRI data. The facial stimuli induced widespread activity within occipital regions, including the fusiform and occipital face area, as well as inferior frontal regions, anterior insula, and medial cingulate cortex (conjunction analysis of SAD, HAP and EN, Supplementary Table S6, see Fig. 2B for difference contrasts between emotional and neutral stimuli). Treatment effects were examined using the contrasts of oxytocin $>$ placebo, placebo $>$ oxytocin and in interactions with affective facial expression. There were no effects of treatment in both whole-brain analyses and ROI analyses. Whole-brain analyses showed that on average, genotype was significantly associated with a small cluster within the right primary visual cortex ($k = 2$, $20/-100/0$, $F(1,130) = 25.21$, $p_{FWE} = 0.031$).

When controlling for age, the effect of genotype was no longer significant. When controlling for dose, the genotype effect was significant in two additional small clusters ($k_s \leq 5$) in the left fusiform gyrus ($-28/-76/-16$, $F(1,128) = 30.18$, $p_{FWE} < 0.001$) and right lingual gyrus ($16/-84/-6$, $F(1,128) = 26.97$). Otherwise, controlling for age, dose, and order of treatment did not change the magnitude of the effects (Supplementary Fig. S3). On average, age was associated with activation within the right middle occipital gyrus ($k = 25$, $-18/-100/2$, $F(1,128) = 36.89$, $p_{FWE} < 0.001$), and dose was associated with activation within left middle occipital gyrus ($k = 66$, $-42/-80/-2$, $F(1,128) = 42.12$, $p_{FWE} < 0.001$) and right lingual gyrus ($k = 29$, $16/-82/-6$, $F(1,128) = 35.25$, $p_{FWE} = 0.001$). Age, dose, and order did not significantly interact with treatment.

Social pain. *Behavioral data.* Empathy for others' social pain was successfully induced, as shown by a significant main effect of category ($F(1,19) = 1413.25$, $p < 0.001$, partial $\eta^2 = 0.987$). There were no significant main effects of treatment or $OXTR$ genotype, and no significant interaction effects. Controlling for age, dose, and order of treatment did not change the magnitude of these effects (Supplementary Table S12).

Functional MRI data. Whole-brain analyses revealed that SP, compared to SN, elicited significant activation in posterior temporal regions, posterior medial frontal gyrus, thalamus, inferior frontal gyrus, and supramarginal gyrus (Supplementary Table S7, Fig. 2B). Treatment effects were examined using the contrasts of oxytocin > placebo, placebo > oxytocin and in interactions with stimulus category. Again, there were no significant treatment effects in both whole-brain analyses and ROI analyses, and no significant effects of genotype or genotype-treatment interactions.

When controlling for dose, genotype was on average significantly associated with activation within the right lingual gyrus ($k = 43$, $16/-84/-6$, $F(1,116) = 34.49$, $p_{FWE} = 0.001$). Otherwise, controlling for age, dose or order did not change the magnitude of effects (Supplementary Fig. S4). On average, age was significantly associated with activation in a cluster within the left inferior occipital gyrus ($k = 8$, $-36/-90/-10$, $F(1,116) = 32.73$, $p_{FWE} = 0.002$). Age, dose, and order did not significantly interact with treatment.

Discussion

The present study examined the influence of acute oxytocin administration on neural correlates of empathy in individuals with ASD and how these effects are modulated by *OXTR* genotype. While all three tasks elicited activation within networks related to sharing another person's affective state, our findings are inconclusive regarding the effects of oxytocin on brain activation. Of all analyses across three experiments, including analyses restricted to anatomically defined search areas, we found only one significant effect of oxytocin on brain activation. All other comparisons yielded non-significant results. *OXTR* genotype did not significantly influence oxytocin efficacy in the hypothesized regions. Exploratory analyses showed that controlling for participant age, received dose and order of treatment administration did not influence treatment effects.

Overall, our results are part of a growing number of studies that report heterogeneous effects of intranasal oxytocin in the context of ASD. While most randomized clinical trials have found some oxytocin effects on ASD symptoms^{33,50–52} and brain function^{50–52,80,81}, not all trials have reported effects⁸². Importantly, our findings are in line with recent meta-analytical evidence indicating that intranasal oxytocin only leads to small but non-significant changes in overall social cognition in ASD⁴⁴, but has no significant effect on emotion recognition and empathy⁸³.

The only significant oxytocin effect on brain activation was found during the physical pain experiment, where oxytocin, compared to placebo, enhanced activation in bilateral amygdala and left hippocampus, irrespective of whether the pictures showed painful scenes or not. While this finding fits with previous reports that oxytocin administration leads to an increase in amygdala activation during the processing of faces in men with ASD^{51,52}, these findings are not consistent with studies that examine neural responses to aversive stimuli in men without an ASD diagnosis. These studies have repeatedly demonstrated decreased amygdala activation, which has been interpreted as a neural mechanism underlying oxytocin's anxiolytic effects^{18,20,21}. Further, our result of increased amygdala activation is not in line with previous studies examining empathy for others' physical pain in men without ASD, showing reduced activation in the left insula after oxytocin administration⁸⁴. The increase in amygdala reactivity during the physical pain task might be specific to ASD and reflect increased sensitivity in a context involving the potential injury to another person, regardless of whether the injury actually occurs. This would however suggest that oxytocin leads to a less differentiated response to the pain or absence of pain in others, which might in fact reflect a less empathic state than under placebo conditions. However, given that the effects on the brain level were not associated with robust behavioral effects, and that this was the only significant oxytocin effect found among the multitude of contrasts examined within this study, this interpretation should be considered speculative.

In principle, there are several possible explanations for the predominant absence of general oxytocin effects throughout the remaining analyses. Besides concerns relating to the intranasal method of administration and optimal doses of oxytocin⁸⁵, reasons might lie in the specificity of our sample. First, given our sample size of 25 analyzed datasets, the current study did not have sufficient statistical power to reliably detect possible small effects of intranasal oxytocin. It is therefore unclear whether our findings reflect true null effects or if they are the consequence of data insensitivity. However, it must be noted that our sample is larger than the average sample size of previous studies examining oxytocin effects on brain function in ASD⁴⁴, and comparable to the average sample size in clinical trials examining oxytocin effects across different neurodevelopmental disorders⁸³. Moreover, previous studies showing oxytocin effects on emotion recognition, empathy, or face processing in adults with ASD had an average sample size of 21.5 participants^{48,50,51,86–88}. If the effects found in these studies are true effects with roughly accurate effect size estimates, we would expect to find them even within in our sample. Second, the sample was relatively homogeneous, including only males without intellectual disability and with moderate levels of symptomatology at the time of data collection, which cannot be considered representative for the heterogeneous phenotype of ASD.

Moreover, all participants had received multiple interventions since their initial diagnosis in childhood. Interestingly, carriers of the rs53576 A allele showed higher levels of ASD symptomatology in their childhood compared to non-carriers, but both groups displayed comparable symptom levels at the time of study participation. Possibly, our participants, and especially A allele carriers, might have benefitted from these interventions at such a rate that a ceiling effect was reached for oxytocin efficacy. Further, epigenetic processes might have influenced the sensitivity of A-allele carriers to intranasal oxytocin. There is evidence that the A allele of rs53576 is linked to increased methylation levels of CpG-islands of the *OXTR*^{89,90} and reduces the *OXTR* gene expression in distinct brain regions in individuals with ASD⁹¹. In the same way as allele-specific DNA-methylation might mask or reveal associations between *OXTR* rs53576 genotype and phenotype⁹², it might also impact the effect of intranasal oxytocin on social cognition.

Indeed, we did not find influences of *OXTR* rs53576 genotype on oxytocin effects in this study. This is certainly related to the limited statistical power of our sample, also given the low frequency of homozygous carriers of the A allele. Further, it is more likely that a combination of *OXTR* SNPs and *OXTR* haplotypes, rather than a single SNP, modulates social-cognitive abilities⁹³. Considering multiple *OXTR* SNPs could thus be a way of identifying individuals who benefit most of intranasal oxytocin in future research, if at any point in the future sample sizes provide sufficient power to detect these effects.

It has been frequently discussed that oxytocin effects are influenced by trait-level individual differences and underlying variation in the endogenous oxytocin system⁵³. Although this study explicitly examined potential moderating influences of *OXTR* genotype, other potential moderating factors could not be addressed, which might have led to overall non-significant effects. For example, the age range in this sample was 15–33 years, with a significantly larger proportion of adults (18 years or older). Since oxytocin has been shown to influence brain and behavior differently at different developmental stages⁹⁴, oxytocin efficacy might differ between adults and adolescents. Although controlling for the received dose and age did not change the direction and magnitude of our main results, future studies could examine the influence of age in larger and more balanced groups to obtain higher statistical power. Further, after the preregistration of this study, several studies have been published showing that social anxiety and baseline plasma oxytocin levels can influence oxytocin efficacy in autistic individuals^{87,95,96}. Since we did not measure baseline oxytocin levels or anxiety, we cannot rule out moderating effects of these factors in our sample. However, these effects are still not well understood, and more recent evidence has raised doubts on whether plasma oxytocin levels are significantly related to brain levels under baseline conditions⁹⁷.

An alternative explanation for the absence of a general treatment effect in this study relates to an overestimation of effect sizes of intranasal oxytocin treatment based on earlier studies. It has been criticized that most studies examining oxytocin effects have too small sample sizes to even detect medium effects and are therefore substantially underpowered⁹⁸. Generally, effect sizes of studies using intranasal oxytocin seem to be smaller than initially assumed⁹⁹, a finding that is also reflected in unsuccessful attempts to replicate earlier findings of oxytocin effects on trust^{100,101} and mind-reading in healthy populations¹⁰². Moreover, biases in reporting and publishing results may have contributed to an overestimation of effect sizes in human oxytocin research. While there is some evidence that publication bias is present in the broader field of human oxytocin studies¹⁰³, meta-analyses examining publication and researcher bias in oxytocin studies in the context of ASD are rather inconclusive^{44,83}.

The variety of findings of human oxytocin studies have led to several notions about how oxytocin generally influences social behavior, cognition, and emotion. While some hypothesize that oxytocin specifically targets social processes¹⁰⁴, other models suggest a more general function, such as anxiety reduction¹⁰⁵, regulation of approach/avoidance motivation¹⁰⁶ or allostasis¹⁰⁷. In this context, it is difficult to predict how and if intranasal oxytocin affects social cognition and social affect in ASD. However, to determine oxytocin's therapeutic potential, there is a need for a basic understanding and robust and replicable measures of its effectiveness. In the long run, this can only be achieved by focusing on core psychological processes related to ASD symptoms and using standardized protocols in multiple, heterogeneous samples that can in the end be collapsed to reach enough power. Encouraging replication studies will enable researchers to achieve a nuanced understanding of how and if oxytocin effectiveness is moderated by biological factors (e.g. genetic variation, brain development and endogenous oxytocin levels), personality traits, symptom severity and comorbidities, and which specific psychological processes are targeted under which circumstances. Whether or not oxytocin nasal spray may benefit individuals with ASD, either as a discrete treatment option or in combination with behavioral therapy, cannot be assessed to date.

Conclusions

In conclusion, our study does not provide support for effects of a single dose of oxytocin on neural processes underlying an affective route to understanding others in males with ASD without intellectual disability. While variation of the rs53576 SNP on the *OXTR* did not influence the efficacy of oxytocin in our sample, genetic modulation of oxytocin effects on empathy cannot be ruled out. The effects of a single dose of intranasal oxytocin might have been too small to lead to a detectable change in brain function and affective experience in our sample of 25 individuals, which might suggest that its use as a therapeutic intervention alone may be limited. An in-depth understanding of how oxytocin is relevant to the heterogeneous phenotype of ASD can be achieved by considering moderating individual factors, using paradigms capturing clinically relevant psychological processes in sufficiently large samples, and reporting findings in an unbiased fashion.

Data availability

The datasets generated and analyzed during the current study are not publicly available due to them containing information that could compromise research participant privacy and consent. Fully anonymized data are available from the corresponding author on reasonable request.

Received: 21 July 2020; Accepted: 30 June 2021

Published online: 23 July 2021

References

1. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*, 5th ed. (American Psychiatric Association, 2013).
2. Bai, D. *et al.* Association of genetic and environmental factors with autism in a 5-country cohort. *JAMA Psychiat.* <https://doi.org/10.1001/jamapsychiatry.2019.1411> (2019).
3. Brewer, N., Young, R. L. & Barnett, E. Measuring theory of mind in adults with autism spectrum disorder. *J. Autism Dev. Disord.* **47**, 1927–1941 (2017).

4. Senju, A. Atypical development of spontaneous social cognition in autism spectrum disorders. *Brain Dev.* **35**, 96–101 (2013).
5. Gallese, V., Rochat, M. J. & Berchio, C. The mirror mechanism and its potential role in autism spectrum disorder. *Dev. Med. Child Neurol.* **55**, 15–22 (2013).
6. Keysers, C. & Gazzola, V. Expanding the mirror: Vicarious activity for actions, emotions, and sensations. *Curr. Opin. Neurobiol.* **19**, 666–671 (2009).
7. Krach, S. *et al.* Evidence from pupillometry and fMRI indicates reduced neural response during vicarious social pain but not physical pain in autism. *Hum. Brain Mapp.* **36**, 4730–4744 (2015).
8. Oberman, L. M. *et al.* EEG evidence for mirror neuron dysfunction in autism spectrum disorders. *Cogn. Brain Res.* **24**, 190–198 (2005).
9. Hadjikhani, N., Joseph, R. M., Snyder, J. & Tager-Flusberg, H. Anatomical differences in the mirror neuron system and social cognition network in autism. *Cereb. Cortex* **16**, 1276–1282 (2006).
10. Dapretto, M. *et al.* Understanding emotions in others: Mirror neuron dysfunction in children with autism spectrum disorders. *Nat. Neurosci.* **9**, 28–30 (2006).
11. Kanske, P., Böckler, A. & Singer, T. *Models, Mechanisms and Moderators Dissociating Empathy and Theory of Mind*. 193–206. https://doi.org/10.1007/7854_2015_412 (Springer, 2015).
12. Gallese, V., Keysers, C. & Rizzolatti, G. A unifying view of the basis of social cognition. *Trends Cogn. Sci.* **8**, 396–403 (2004).
13. Brownstein, M. J., Russell, J. T. & Gainer, H. Synthesis, transport, and release of posterior pituitary hormones. *Science (80-)*. **207**, 373–378 (1980).
14. Meyer-Lindenberg, A., Domes, G., Kirsch, P. & Heinrichs, M. Oxytocin and vasopressin in the human brain: Social neuropeptides for translational medicine. *Nat. Rev. Neurosci.* **12**, 524–538 (2011).
15. Domes, G., Heinrichs, M., Michel, A., Berger, C. & Herpertz, S. C. Oxytocin improves ‘mind-reading’ in humans. *Biol. Psychiatry* **61**, 731–733 (2007).
16. Hurlemann, R. *et al.* Oxytocin enhances amygdala-dependent, socially reinforced learning and emotional empathy in humans. *J. Neurosci.* **30**, 4999–5007 (2010).
17. Wigton, R. *et al.* Neurophysiological effects of acute oxytocin administration: Systematic review and meta-analysis of placebo-controlled imaging studies. *J. Psychiatry Neurosci.* **40**, E1–E22 (2015).
18. Domes, G. *et al.* Oxytocin attenuates amygdala responses to emotional faces regardless of valence. *Biol. Psychiatry* **62**, 1187–1190 (2007).
19. Quintana, D. S. *et al.* Low dose intranasal oxytocin delivered with Breath Powered device dampens amygdala response to emotional stimuli: A peripheral effect-controlled within-subjects randomized dose-response fMRI trial. *Psychoneuroendocrinology* **69**, 180–188 (2016).
20. Kirsch, P. Oxytocin modulates neural circuitry for social cognition and fear in humans. *J. Neurosci.* **25**, 11489–11493 (2005).
21. Gamer, M., Zurowski, B. & Büchel, C. Different amygdala subregions mediate valence-related and attentional effects of oxytocin in humans. *Proc. Natl. Acad. Sci.* **107**, 9400–9405 (2010).
22. Petrovic, P., Kalisch, R., Singer, T. & Dolan, R. J. Oxytocin attenuates affective evaluations of conditioned faces and amygdala activity. *J. Neurosci.* **28**, 6607–6615 (2008).
23. Geng, Y. *et al.* Oxytocin enhancement of emotional empathy: Generalization across cultures and effects on amygdala activity. *Front. Neurosci.* **12**, 1–14 (2018).
24. Boccia, M. L., Petrusz, P., Suzuki, K., Marson, L. & Pedersen, C. A. Immunohistochemical localization of oxytocin receptors in human brain. *Neuroscience* **253**, 155–164 (2013).
25. Rodrigues, S. M., Saslow, L. R., Garcia, N., John, O. P. & Keltner, D. Oxytocin receptor genetic variation relates to empathy and stress reactivity in humans. *Proc. Natl. Acad. Sci.* **106**, 21437–21441 (2009).
26. Smith, K. E., Porges, E. C., Norman, G. J., Connelly, J. J. & Decety, J. Oxytocin receptor gene variation predicts empathic concern and autonomic arousal while perceiving harm to others. *Soc. Neurosci.* **9**, 1–9 (2014).
27. Li, J. *et al.* Association of oxytocin receptor gene (OXTR) rs53576 polymorphism with sociality: A meta-analysis. *PLoS One* **10**, 1–16 (2015).
28. Uzefovsky, F. *et al.* Oxytocin receptor and vasopressin receptor 1a genes are respectively associated with emotional and cognitive empathy. *Horm. Behav.* **67**, 60–65 (2015).
29. Gong, P. *et al.* Revisiting the impact of OXTR rs53576 on empathy: A population-based study and a meta-analysis. *Psychoneuroendocrinology* **80**, 131–136 (2017).
30. Flasbeck, V., Moser, D., Kumsta, R. & Brüne, M. The OXTR single-nucleotide polymorphism rs53576 moderates the impact of childhood maltreatment on empathy for social pain in female participants: Evidence for differential susceptibility. *Front. Psychiatry* **9**, 1–9 (2018).
31. Uzefovsky, F. *et al.* The oxytocin receptor gene predicts brain activity during an emotion recognition task in autism. *Mol. Autism* **10**, 12 (2019).
32. Al-Ayadhi, L. Y. Altered oxytocin and vasopressin levels in autistic children in Central Saudi Arabia. *Neurosciences* **10**, 47–50 (2005).
33. Andari, E. *et al.* Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. *Proc. Natl. Acad. Sci. U. S. A.* **107**, 4389–4394 (2010).
34. Modahl, C. *et al.* Plasma oxytocin levels in autistic children. *Biol. Psychiatry* **43**, 270–277 (1998).
35. Parker, K. J. *et al.* Plasma oxytocin concentrations and OXTR polymorphisms predict social impairments in children with and without autism spectrum disorder. *Proc. Natl. Acad. Sci.* **111**, 12258–12263 (2014).
36. Miller, M. *et al.* Oxytocin and vasopressin in children and adolescents with autism spectrum disorders: Sex differences and associations with symptoms. *Autism Res.* **6**, 91–102 (2013).
37. Cataldo, I., Azhari, A. & Esposito, G. A review of oxytocin and arginine-vasopressin receptors and their modulation of autism spectrum disorder. *Front. Mol. Neurosci.* **11**, 1–20 (2018).
38. LoParo, D. & Waldman, I. D. The oxytocin receptor gene (OXTR) is associated with autism spectrum disorder: A meta-analysis. *Mol. Psychiatry* **20**, 640–646 (2015).
39. Kranz, T. M. *et al.* Meta-analysis and association of two common polymorphisms of the human oxytocin receptor gene in autism spectrum disorder. *Autism Res.* **9**, 1036–1045 (2016).
40. Wilczyński, K. M., Siwiec, A. & Janas-Kozik, M. Systematic review of literature on single-nucleotide polymorphisms within the oxytocin and vasopressin receptor genes in the development of social cognition dysfunctions in individuals suffering from autism spectrum disorder. *Front. Psychiatry* **10**, 380 (2019).
41. Wermter, A. K. *et al.* Evidence for the involvement of genetic variation in the oxytocin receptor gene (OXTR) in the etiology of autistic disorders on high-functioning level. *Am. J. Med. Genet. Part B Neuropsychiatr. Genet.* **153**, 629–639 (2010).
42. Tost, H. *et al.* A common allele in the oxytocin receptor gene (OXTR) impacts prosocial temperament and human hypothalamic-limbic structure and function. *Proc. Natl. Acad. Sci.* **107**, 13936–13941 (2010).
43. Alvares, G. A., Quintana, D. S. & Whitehouse, A. J. O. Beyond the hype and hope: Critical considerations for intranasal oxytocin research in autism spectrum disorder. *Autism Res.* **10**, 25–41 (2017).
44. Ooi, Y., Weng, S.-J., Kossowsky, J., Gerger, H. & Sung, M. Oxytocin and autism spectrum disorders: A systematic review and meta-analysis of randomized controlled trials. *Pharmacopsychiatry* **50**, 5–13 (2016).

45. Guastella, A. J. & Hickie, I. B. Oxytocin treatment, circuitry, and autism: A critical review of the literature placing oxytocin into the autism context. *Biol. Psychiatry* **79**, 234–242 (2016).
46. Bakermans-Kranenburg, M. J. & van IJzendoorn, M. H. Sniffing around oxytocin: Review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy. *Transl. Psychiatry* **3**, e258 (2013).
47. Yamasue, H. Promising evidence and remaining issues regarding the clinical application of oxytocin in autism spectrum disorders. *Psychiatry Clin. Neurosci.* **70**, 89–99 (2016).
48. Guastella, A. J. *et al.* Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. *Biol. Psychiatry* **67**, 692–694 (2010).
49. Anagnostou, E. *et al.* Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: A randomized controlled trial. *Mol. Autism* **3**, 16 (2012).
50. Aoki, Y. *et al.* Oxytocin improves behavioural and neural deficits in inferring others' social emotions in autism. *Brain* **137**, 3073–3086 (2014).
51. Domes, G. *et al.* Effects of intranasal oxytocin on the neural basis of face processing in autism spectrum disorder. *Biol. Psychiatry* **74**, 164–171 (2013).
52. Domes, G., Kumbier, E., Heinrichs, M. & Herpertz, S. C. Oxytocin promotes facial emotion recognition and amygdala reactivity in adults with asperger syndrome. *Neuropsychopharmacology* **39**, 698–706 (2014).
53. Bartz, J. A., Zaki, J., Bolger, N. & Ochsner, K. N. Social effects of oxytocin in humans: Context and person matter. *Trends Cogn. Sci.* **15**, 301–309 (2011).
54. Marsh, A. A. *et al.* The influence of oxytocin administration on responses to infant faces and potential moderation by OXTR genotype. *Psychopharmacology* **224**, 469–476 (2012).
55. Chen, F. S. *et al.* Genetic modulation of oxytocin sensitivity: A pharmacogenetic approach. *Transl. Psychiatry* **5**, e664–e664 (2015).
56. Kosaka, H. *et al.* Oxytocin efficacy is modulated by dosage and oxytocin receptor genotype in young adults with high-functioning autism: A 24-week randomized clinical trial. *Transl. Psychiatry* **6**, e872 (2016).
57. Feng, C. *et al.* A common oxytocin receptor gene (OXTR) polymorphism modulates intranasal oxytocin effects on the neural response to social cooperation in humans. *Genes Brain Behav.* **14**, 516–525 (2015).
58. Montag, C., Sauer, C., Reuter, M. & Kirsch, P. An interaction between oxytocin and a genetic variation of the oxytocin receptor modulates amygdala activity toward direct gaze: Evidence from a pharmacological imaging genetics study. *Eur. Arch. Psychiatry Clin. Neurosci.* **263**, 169–175 (2013).
59. Watanabe, T. *et al.* Oxytocin receptor gene variations predict neural and behavioral response to oxytocin in autism. *Soc. Cogn. Affect. Neurosci.* **12**, 496–506 (2017).
60. Hernandez, L. M. *et al.* Additive effects of oxytocin receptor gene polymorphisms on reward circuitry in youth with autism. *Mol. Psychiatry* **22**, 1134–1139 (2017).
61. Lord, C. *et al.* Autism diagnostic observation schedule (ADOS). *J. Autism Dev. Disord.* <https://doi.org/10.1007/BF02211841> (2000).
62. Rutter, M., Le Couteur, A. & Lord, C. *Autism Diagnostic Interview-Revised (ADI-R)*. (Western Psychological Services, 2003).
63. Wechsler, D. *Wechsler Intelligence Scale for Children—Fourth Edition (WISC-IV)*. (The Psychological Corporation, 2003).
64. Schneider, S. & Margraf, J. *Diagnostisches Interview bei psychischen Störungen (DIPS)*. (Springer, Berlin, 2006).
65. Baron-Cohen, S., Wheelwright, S., Skinner, R., Martin, J. & Clubley, E. The Autism-Spectrum Quotient (AQ): Evidence from Asperger syndrome/high-functioning autism, males and females, scientists and mathematicians. *J. Autism Dev. Disord.* **31**, 5–17 (2001).
66. Baron-Cohen, S. & Wheelwright, S. The Empathy Quotient: An investigation of adults with Asperger syndrome or high functioning autism, and normal sex differences. *J. Autism Dev. Disord.* **34**, 163–175 (2004).
67. Rühl, D., Bölte, S., Feineis-Matthews, S. & Poustka, F. *Diagnostische Beobachtungsskala für Autistische Störungen (ADOS)*. (Huber, 2004).
68. Wermter, A. K. *et al.* Evidence for the involvement of genetic variation in the oxytocin receptor gene (OXTR) in the etiology of autistic disorders on high-functioning level. *Am. J. Med. Genet. Part B Neuropsychiatr. Genet.* <https://doi.org/10.1002/ajmg.b.31032> (2010).
69. Lundqvist, D., Flykt, A. & Öhman, A. The Karolinska directed emotional faces (KDEF). *CD ROM Dep. Clin. Neurosci. Psychol. Sect. Karolinska Institutet* **91**, 630 (1998).
70. Holm, S. A simple sequentially rejective multiple test procedure. *Scand. J. Stat.* **6**, 65–70 (1979).
71. Jackson, P. L., Meltzoff, A. N. & Decety, J. How do we perceive the pain of others? A window into the neural processes involved in empathy. *Neuroimage* **24**, 771–779 (2005).
72. Krach, S. *et al.* Your flaws are my pain: Linking empathy to vicarious embarrassment. *PLoS One* **6**, e18675 (2011).
73. Paulus, F. M., Müller-Pinzler, L., Jansen, A., Gazzola, V. & Krach, S. Mentalizing and the role of the posterior superior temporal sulcus in sharing others' embarrassment. *Cereb. Cortex* **25**, 2065–2075 (2015).
74. Tzourio-Mazoyer, N. *et al.* Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. *Neuroimage* <https://doi.org/10.1006/nimg.2001.0978> (2002).
75. Maldjian, J. A., Laurienti, P. J., Kraft, R. A. & Burdette, J. H. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. *Neuroimage* **19**, 1233–1239 (2003).
76. Kelly, C. *et al.* A convergent functional architecture of the insula emerges across imaging modalities. *Neuroimage* **61**, 1129–1142 (2012).
77. Wickham, H. *ggplot2: Elegant Graphics for Data Analysis* (Springer, 2016).
78. R Core Team. *R: A Language and Environment for Statistical Computing*. (2020).
79. Lamm, C., Decety, J. & Singer, T. Meta-analytic evidence for common and distinct neural networks associated with directly experienced pain and empathy for pain. *Neuroimage* **54**, 2492–2502 (2011).
80. Aoki, Y. *et al.* Oxytocin's neurochemical effects in the medial prefrontal cortex underlie recovery of task-specific brain activity in autism: A randomized controlled trial. *Mol. Psychiatry* **20**, 447–453 (2015).
81. Andari, E., Richard, N., Leboyer, M. & Sirigu, A. Adaptive coding of the value of social cues with oxytocin, an fMRI study in autism spectrum disorder. *Cortex* **76**, 79–88 (2016).
82. Dadds, M. R. *et al.* Nasal oxytocin for social deficits in childhood autism: A randomized controlled trial. *J. Autism Dev. Disord.* **44**, 521–531 (2014).
83. Keech, B., Crowe, S. & Hocking, D. R. Intranasal oxytocin, social cognition and neurodevelopmental disorders: A meta-analysis. *Psychoneuroendocrinology* **87**, 9–19 (2018).
84. Bos, P. A., Montoya, E. R., Hermans, E. J., Keysers, C. & Van Honk, J. Oxytocin reduces neural activity in the pain circuitry when seeing pain in others. *Neuroimage* **113**, 217–224 (2015).
85. Leng, G. & Ludwig, M. Intranasal oxytocin: Myths and delusions. *Biol. Psychiatry* **79**, 243–250 (2016).
86. Watanabe, T. *et al.* Mitigation of sociocommunicational deficits of autism through oxytocin-induced recovery of medial prefrontal activity a randomized trial. *JAMA Psychiat.* **71**, 166–175 (2014).
87. Kanat, M. *et al.* Restoring effects of oxytocin on the attentional preference for faces in autism. *Transl. Psychiatry* <https://doi.org/10.1038/tp.2017.67> (2017).

88. Quintana, D. S. *et al.* Dose-dependent social-cognitive effects of intranasal oxytocin delivered with novel Breath Powered device in adults with autism spectrum disorder: A randomized placebo-controlled double-blind crossover trial. *Transl. Psychiatry* **7**, e1136 (2017).
89. Ziegler, C. *et al.* Oxytocin receptor gene methylation: Converging multilevel evidence for a role in social anxiety. *Neuropsychopharmacology* **40**, 1528–1538 (2015).
90. Reiner, I. *et al.* Methylation of the oxytocin receptor gene in clinically depressed patients compared to controls: The role of OXTR rs53576 genotype. *J. Psychiatr. Res.* **65**, 9–15 (2015).
91. Gregory, S. G. *et al.* Genomic and epigenetic evidence for oxytocin receptor deficiency in autism. *BMC Med.* **7**, 62 (2009).
92. Rijlaarsdam, J. *et al.* Prenatal stress exposure, oxytocin receptor gene (OXTR) methylation, and child autistic traits: The moderating role of OXTR rs53576 genotype. *Autism Res.* **10**, 430–438 (2017).
93. Slane, M. M. *et al.* Social cognition, face processing, and oxytocin receptor single nucleotide polymorphisms in typically developing children. *Dev. Cogn. Neurosci.* **9**, 160–171 (2014).
94. Miller, T. V. & Caldwell, H. K. Oxytocin during development: Possible organizational effects on behavior. *Front. Endocrinol. (Lausanne)* **6**, 76 (2015).
95. Althaus, M. *et al.* Do blood plasma levels of oxytocin moderate the effect of nasally administered oxytocin on social orienting in high-functioning male adults with autism spectrum disorder?. *Psychopharmacology* **233**, 2737–2751 (2016).
96. Parker, K. J. *et al.* Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism. *Proc. Natl. Acad. Sci.* **114**, 201705521 (2017).
97. Valstad, M. *et al.* The correlation between central and peripheral oxytocin concentrations: A systematic review and meta-analysis. *Neurosci. Biobehav. Rev.* **78**, 117–124 (2017).
98. Walum, H., Waldman, I. D. & Young, L. J. Statistical and methodological considerations for the interpretation of intranasal oxytocin studies. *Biol. Psychiatry* **79**, 251–257 (2016).
99. Tabak, B. A. *et al.* Null results of oxytocin and vasopressin administration across a range of social cognitive and behavioral paradigms: Evidence from a randomized controlled trial. *Psychoneuroendocrinology* <https://doi.org/10.1016/j.psyneuen.2019.04.019> (2019).
100. Lane, A. *et al.* Failed replication of oxytocin effects on trust: The envelope task case. *PLoS One* **10**, 1–10 (2015).
101. Declerck, C. H., Boone, C., Pauwels, L., Vogt, B. & Fehr, E. A registered replication study on oxytocin and trust. *Nat. Hum. Behav.* <https://doi.org/10.1038/s41562-020-0878-x> (2020).
102. Radke, S. & de Bruijn, E. R. A. Does oxytocin affect mind-reading? A replication study. *Psychoneuroendocrinology* <https://doi.org/10.1016/j.psyneuen.2015.06.006> (2015).
103. Lane, A., Luminet, O., Nave, G. & Mikolajczak, M. Is there a publication bias in behavioural intranasal oxytocin research on humans? Opening the file drawer of one laboratory. *J. Neuroendocrinol.* **28**, 1–15 (2016).
104. Shamay-Tsoory, S. G. & Abu-Akel, A. The social salience hypothesis of oxytocin. *Biol. Psychiatry* **79**, 194–202 (2016).
105. Neumann, I. D. & Slattery, D. A. Oxytocin in general anxiety and social fear: A translational approach. *Biol. Psychiatry* **79**, 213–221 (2016).
106. Harari-Dahan, O. & Bernstein, A. A general approach—avoidance hypothesis of Oxytocin: Accounting for social and non-social effects of oxytocin. *Neurosci. Biobehav. Rev.* **47**, 506–519 (2014).
107. Quintana, D. S. & Guastella, A. J. An allostatic theory of oxytocin. *Trends Cogn. Sci.* <https://doi.org/10.1016/j.tics.2020.03.008> (2020).

Acknowledgements

We would like to thank the participants for their willingness to help in this study. We are grateful to G. Gerber (study nurse), A. Thum, H. Barth, A. Gröb, H. Schmidt, R. Werner, M. Wallnig and P. Herholz for their assistance in the conduct of this research.

Author contributions

A.W., S.K., F.M.P. and I.K.B. designed the study. I.K.B. was responsible for study coordination. A.W. and S.S. were responsible for recruitment, data collection and implementation of the study. M.H. and T.S. performed the medical examinations. P.A. assessed the ECG findings. A.V.M., F.M.P. and S.K. analyzed the data. A.V.M., F.M.P., S.K., A.W., S.S. and I.K.B. discussed the findings. A.V.M. drafted this paper, which was read and revised by all authors.

Funding

Open Access funding enabled and organized by Projekt DEAL. This study was funded by a grant of the German Research Foundation (DFG Grant WE 5076/1-1).

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-021-94407-x>.

Correspondence and requests for materials should be addressed to A.V.M.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021